Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen, an aesthetic and therapeutic company, has completed all injections in the Phase II/III study IT-A-008 investigating Isolagen Therapy for the treatment of moderate to severe facial acne scars.
Subscribe to our email newsletter
Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.
The Isolagen process is said to be an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient’s own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient’s skin. This treatment, known as the Isolagen Therapy, is designed to improve skin damage caused by the normal effects of aging, sun damage, acne and burns.
Declan Daly, CEO of Isolagen, said: “We are very excited that our acne program is progressing on time and we believe the dermatology community will be very interested in this data early next year because of the unmet need for a minimally invasive acne scar treatment. Our current priority is to gain additional funding and secure a strategic partner to help us deliver on the exciting clinical promise of the Isolagen therapy in all of these areas.”